Tesamorelin (Egrifta) Pricing: April 2026
Tesamorelin spans a 100x price gap: Egrifta WR retail at $3,000–$10,000+/mo (often $0 with THERA copay), compounded telehealth from $199/mo, research vials from $36.
Tesamorelin is a synthetic 44-amino-acid GHRH analog that stimulates endogenous growth hormone release. It is FDA-approved as Egrifta (manufactured by Theratechnologies) for the reduction of excess visceral abdominal fat in adults with HIV-associated lipodystrophy — the only FDA-approved treatment for that indication.
The product line has evolved: the original Egrifta was replaced by Egrifta SV (F4, daily reconstitution, approved 2019, being phased out) and now Egrifta WR (F8, weekly reconstitution, approved March 2025), which is patent-protected in the US through 2033.
Off-label use: Tesamorelin is widely prescribed off-label for anti-aging, visceral fat reduction, liver fat reduction (NASH/MASLD), and body composition optimization. Clinical data shows ~15–20% VAT reduction over 26 weeks. Dosing is typically 1.28–2 mg subcutaneous daily.
Regulatory note (April 2026): Tesamorelin was reclassified as a biologic product on March 23, 2020 under the BPCIA, making it technically ineligible for 503A/503B compounding exemptions. Despite this, compounding pharmacies and telehealth platforms widely prepare and dispense compounded tesamorelin in a legal gray zone. This situation is distinct from the Category 2 peptide issues affecting BPC-157 and others.
Price spread: The 100x gap between research-vial pricing ($36–$79) and branded Egrifta retail ($3,000–$10,000+/mo) is extreme, but the compounded telehealth channel ($150–$300/mo) is the dominant real-world access path for off-label use.
Egrifta SV / Egrifta WR (FDA-Approved, Branded)
The branded Theratechnologies product, available only through specialty pharmacies (Accredo, AnovoRx) as a limited distribution drug. Insurance typically covers only for HIV-associated lipodystrophy with prior authorization.
| Channel | Price | Source |
|---|---|---|
| THERA Patient Assistance Program (Uninsured) | $0/mo | EGRIFTA WR |
| THERA Copay Card (Commercially Insured) | $0–$50/mo | THERA Patient Support |
| Prescription Hope (Broker Service) | ~$60/mo | Prescription Hope |
| Insurance Copay (With Prior Auth) | $50–$500/mo | SaveHealth |
| Retail / Cash Price (Egrifta SV) | ~$3,085+/mo | PrymaLab |
| List Price (Egrifta SV, Alt Config) | ~$10,673/mo | SaveHealth |
Telehealth Platforms (Compounded)
Telehealth clinics prescribing compounded tesamorelin for off-label use. The dominant real-world access channel for non-HIV-LD patients. Pricing typically bundles consultation, compounded medication, and shipping.
| Channel | Price | Source |
|---|---|---|
| Team Wellcore | From $199/mo | Team Wellcore |
| LIVV Natural | $207.50/5mg vial | Better Results Book |
| TRT Nation | $233/mo | Better Results Book |
| General Telehealth Range | $150–$300/mo | PrymaLab |
| Ivy Rx (Premium Tier) | $1,000–$2,500/mo | Ivy Rx |
Compounding Pharmacies (Rx Required)
Tesamorelin's biologic reclassification in 2020 makes it technically ineligible for 503A compounding, but compounded supply continues to reach patients, primarily through integrated telehealth clinics. Most compounding pharmacies do not publicly list tesamorelin availability.
| Channel | Price | Source |
|---|---|---|
| Compounding Pharmacy (Medication Only) | $150–$300/mo | Better Results Book |
| Empower Pharmacy | Contact for availability | Empower Pharmacy |
Research Peptide Vendors (Research Use Only)
Sold strictly for in-vitro research purposes, not for human use. Prices are per-vial. Requires reconstitution with bacteriostatic water. Included for market context.
| Channel | Price | Source |
|---|---|---|
| SwissChems (2mg) | ~$30–$50/vial | SwissChems |
| Empower Peptides (Research) | $37–$58/vial | Empower Peptides |
| Core Peptides (5mg) | $43/vial | Core Peptides |
| Core Peptides (10mg) | $79/vial | Core Peptides |